In the past number of years, the united kingdom has witnessed a revolution in clinical pounds‑decline solutions — in the introduction of semaglutide (Wegovy®) to the increasing popularity of tirzepatide (Mounjaro®). Now, One more name is drawing attention in equally clinical and community overall